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Choroid plexus genes for CSF production 
and brain homeostasis are altered in Alzheimer’s 
disease
Shawn Kant1, Edward G. Stopa1, Conrad E. Johanson2, Andrew Baird3 and Gerald D. Silverberg4*
Abstract 
Background: The roles of the choroid plexus (CP) and cerebrospinal fluid (CSF) production have drawn increasing 
attention in Alzheimer’s disease (AD) research. Specifically, studies document markedly decreased CSF production 
and turnover in moderate-to-severe AD. Moreover, reduced CP function and CSF turnover lead to impaired clearance 
of toxic metabolites, likely promote neuroinflammation, and may facilitate neuronal death during AD progression. We 
analyzed CP gene expression in AD compared with control subjects, specifically considering those genes involved 
with CSF production and CP structural integrity.
Methods: The Brown-Merck Gene Expression Omnibus (GEO) database (CP transcripts) was mined to examine 
changes in gene expression in AD compared to controls with a focus on assorted genes thought to play a role in CSF 
production. Specifically, genes coding for ion transporters in CP epithelium (CPE) and associated enzymes like Na–K-
ATPase and carbonic anhydrase, aquaporins, mitochondrial transporters/enzymes, blood–cerebrospinal fluid barrier 
(BCSFB) stability proteins, and pro-inflammatory mediators were selected for investigation. Data were analyzed using t 
test p-value and fold-change analysis conducted by the GEO2R feature of the GEO database.
Results: Significant expression changes for several genes were observed in AD CP. These included disruptions to ion 
transporters (e.g., the solute carrier gene SLC4A5, p = 0.004) and associated enzyme expressions (e.g., carbonic anhy-
drase CA4, p = 0.0001), along with decreased expression of genes involved in BCSFB integrity (e.g., claudin CLDN5, 
p = 0.039) and mitochondrial ATP synthesis (e.g., adenosine triphosphate ATP5L, p = 0.0004). Together all changes 
point to disrupted solute transport at the blood–CSF interface in AD. Increased expression of pro-inflammatory (e.g., 
interleukin IL1RL1, p = 0.00001) and potential neurodegenerative genes (e.g., amyloid precursor APBA3, p = 0.002) 
also implicate disturbed CP function.
Conclusions: Because the altered expression of numerous transcripts in AD-CP help explain decreased CSF produc-
tion in AD, these findings represent a first step towards identifying novel therapeutic targets in AD.
Keywords: CSF production, Homeostasis, Blood–CSF barrier, Blood–brain barrier, Choroid plexus Gene Expression 
Omnibus, Solute carrier families, Choroidal tight junctions, Barrier permeability, Choroid plexus transcriptome, Beta 
amyloid, Mitochondria
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Background
Alzheimer’s disease (AD) is a neurodegenerative disorder 
marked by cognitive, memory and behavioral impair-
ment that significantly interferes with social and occupa-
tional functioning. It is an incurable disease, at present, 
with a long preclinical period and progressive course. In 
AD, amyloid-beta (Aβ) peptide plaques develop in the 
hippocampus, and in other areas of the cerebral cortex. 
Whether plaques themselves cause AD or whether they 
are a by-product of the AD process remains unknown.
The roles of the blood–cerebrospinal fluid (CSF) bar-
rier (BCSFB) and CSF itself in the pathogenesis of AD 
are receiving increasing attention [1–5]. Like the blood–
brain barrier (BBB), the BCSFB functions as a trans-
port interface, facilitating exchange of solutes and  H2O 
between plasma and CSF [6]. The four choroid plexuses 
(CP), one in each ventricle, are the anatomic substrate of 
the BCSFB and are responsible for more than 60–75% of 
CSF production [7] with the remainder produced by the 
ventricular ependyma and BBB. At the cellular level, CP 
epithelium (CPE) cells are continuous with the ventricu-
lar ependymal layer and have apical microvilli. However, 
unlike the tight junctions of the BBB between capillary 
endothelial cells, the tight junctions of the BCSFB are 
located only at the apical portion of the CPE. In humans, 
normal CSF secretion ranges from 400 to 600 ml/day [1, 
7].
Production of CSF by CP occurs in two major sequen-
tial steps: passive fluid ultrafiltration across CP capillaries 
and active ion transport across the CPE [7, 8]. A pressure 
gradient first filters plasma from choroidal capillaries 
into the interstitial compartment of the CP [9]. Carbonic 
anhydrases catalyze conversion of  H2O and  CO2 to  H+ 
and  HCO3− ions. Ion co-transporters and exchang-
ers translocate  Na+,  K+,  Cl−, and  HCO3− ions from the 
interstitial fluid across the basolateral membrane into the 
CPE cell and then, after cytoplasmic swirling, across the 
apical membrane into the ventricles by energy-depend-
ent active transport [10–15]. Water flows across the CPE 
from plasma to ventricular lumen (e.g., through aquapor-
ins) in concordance with prevailing osmotic solute gradi-
ents [16].
Considerable neurodegeneration research has focused 
on increased BBB permeability and decreased efficiency 
of Aβ peptide clearance across the BBB in aging and in 
AD [17–19]. Interestingly, just as in the BBB, tight junc-
tions in CP lose integrity during AD progression. This is 
consistent with increased paracellular permeability and 
BCSFB breaching [20, 21]. Indeed, many of the struc-
tural changes that occur in the AD CP are among the 
first signs of the disease in a subset of patients, including 
extensive atrophy of the CPE that resembles analogous 
changes seen in accelerated aging [20].
Clinical evidence also points to significantly decreased 
CSF production rates in moderate-to-severe stages of AD 
versus normal controls [1]. For example, CSF production 
is ~ 1/2 normal and CSF turnover, defined as the volume 
of CSF produced in 24  h divided by the volume of the 
CSF space, is reduced by threefold, from four times to 
once per day in AD subjects compared to age-matched 
controls [1, 2].
Current theory suggests that CSF hydrostatic pres-
sure initially rises during early AD before falling again in 
later-stage AD, as reduced CSF production outpaces the 
decreased CSF absorption [22]. Decreased CSF produc-
tion and turnover in AD have significant consequences 
for removing toxic metabolites from the CNS. For exam-
ple, altered CPE cholesterol metabolism may affect Aβ 
clearance from CSF [23]. Diminished CSF production 
also decreases the ability of CP-secreted transthyretin 
(TTR) to circulate throughout the CNS via the CSF and 
bind to and stabilize Aβ deposits [20].
Taken together, these findings highlight the need to 
elucidate gene-linked predisposition to pathology in 
CP, CSF, and BCSFB, and how modified transcript pro-
duction adversely affects CP–CSF solute homeostasis 
and neuropathology. Of particular interest are the spe-
cific genetic factors behind impaired CSF production 
and turnover in AD. We investigated genes known to be 
involved in these processes for expression differences 
between healthy and AD-affected CP. These data inform 
on genes that most strongly affect the outcome of CSF 
production and potentially have the strongest impact on 
AD pathology progression in the CP–CSF–brain system.
Methods
A choroid plexus Gene Expression Omnibus (GEO) 
database archived at https ://www.ncbi.nlm.nih.gov/geo/
query /acc.cgi?acc=GSE11 0226 under the GEO accession 
number GSE110226 was mined for gene expression dif-
ferences between choroid plexus from control and AD 
subject brains.
Subject matter
The Brown-Merck database was created using transcrip-
tome-wide Affymetrix microarray assays (Affymetrix, 
Santa Clara, CA, USA) to examine gene expression via 
extracted RNA from human CP tissue samples [24]. RNA 
was extracted with TRIzol reagent by the Thermo-Fisher 
protocol (Thermo-Fisher, Grand Island, NY, USA). Lat-
eral ventricle CP tissue samples were taken from six con-
trol cases, seven late-stage AD cases, four frontotemporal 
dementia cases, and three Huntington’s disease cases. 
Tissue samples were post-mortem, mean post mortem 
interval (PMI) of 22  h for controls, 17  h for AD. Until 
processing could occur, tissues were snap frozen in liquid 
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nitrogen and stored at − 80  °C at the Brown University 
Brain Tissue for Neurodegenerative Disorders Resource 
Center. For this study, we only mined data for gene 
expression level differences between control and AD 
cases. AD cases were slightly older than controls. This is 
an advantage because older people and those with early 
AD often show no significant differences in gene expres-
sion (personal observation by author EGS from prior 
gene studies).
Genes of interest (GoI) were selected based on their 
known or purported significance to CP function and/
or CSF production. For example, genes and mRNA that 
express solute transporters in CPE are integral to CSF 
production [25]. Specifically, genes involved in the active 
transport of ions (along with the obligatory transport of 
 H2O) from blood to the ventricular lumen are the final 
pathway of CSF production; these are considered rate-
limiting genes. Therefore we focus considerable attention 
on genes for Na–K-ATPase, the Na–K–Cl cotransporter, 
and other components of this final secretory pathway.
GoI involved in mitochondrial ATP synthesis and ion 
transport were also selected. Without sufficient mito-
chondrial energy production, the active ion transporters 
in CP cannot operate normally. Intracellular bicarbonate 
production facilitates  HCO3−-dependent  Na+ and  Cl− 
exchange across the CPE [26–29]. In this vein, we con-
sider the carbonic anhydrase family, along with several 
members of the solute carrier (SLC) gene family respon-
sible for  HCO3− exchange and transport. Genes encoding 
BCSFB structural elements for maintenance of regulated 
solute transport were considered as well, along with pro-
inflammatory and neurodegenerative genes capable of 
damaging the BCSFB.
Statistical methods
Gene expression differences between control and 
AD samples in the database were determined using 
the GEO2R search feature of the GEO database. This 
approach creates different groups of samples based on 
unifying characteristics for each group. GEO2R then gen-
erates statistics for gene expression comparisons between 
groups. Examining visual profiles depicting mRNA 
expression levels for each sample in the AD versus con-
trol groups generated by GEO2R, allowed visualization of 
upregulation versus downregulation of various genes in 
AD compared with control CP tissue.
The Brown-Merck database was first mined to identify 
which specific genes involved in CSF production and CP 
function differed in expression between control and AD 
samples. Separate tables were then composed for genes 
that were upregulated, downregulated or unchanged in 
AD. Significance was assessed with t-test p value analyses 
of each gene. An α of < 0.05 was deemed significant. The 
sign of the moderated t statistic of each gene confirmed 
the direction of gene expression changes (upregulation 
or downregulation) seen in the visual mRNA expression 
profiles.
Fold changes to quantify the magnitude of gene expres-
sion differences between control and AD groups were 
determined through GEO2R log base 2 fold change (log2 
FC) analysis, reported as log2FC values. GEO2R took the 
difference between log2 of the gene expression value of 
a given gene in the control group and log2 of the gene 
expression value of that same given gene in the AD group 
to produce log2FC in the tables. Hence positive log2FC 
values signify downregulation in AD relative to control 
and negative log2FC values signify upregulation in AD 
relative to control. Additional file  1 gives actual gene 
expression values for each gene studied.
Results
We investigated expression levels of several different 
genes and gene families that are purported to impact CP 
structural integrity and CSF production. The SLC family 
of genes, for example, appears responsible for consider-
able ion and  H2O transport across CPE [25]. Within the 
SLC group, there was diversified expression in control 
versus AD. Certain genes for  HCO3− exchange and co-
transport (SLC4 subfamily) had decreased expression in 
AD, including SLC4A10 (p = 0.028, log2FC = 0.039) and 
SLC4A5 (p = 0.004, log2FC = 1.12). Other SLC genes 
with decreased expression include the Na–K–Cl co-
transporters SLC12A1 (p = 0.035, log2FC = 1.05) and 
SLC12A2 (p = 0.005, log2FC = 0.38). Table  1 compiles 
downregulated CP genes in the Brown-Merck database 
relevant to CSF production, energy production and CP 
structural integrity. Included in each table is the fold-
change (log2 FC) in expression between AD and control.
Among the upregulated SLC genes in AD CP were 
mitochondrial Fe transporters: SLC25A37 (p = 0.0001, 
log2FC = − 0.64) and SLC25A28 (p = 0.0001, 
log2FC = − 0.64). Other ion-transporters, like the 
KCC4 K–Cl cotransporter SLC12A6 (p = 0.026, 
log2FC = − 0.67) and the organic anion clearance trans-
porter SLCO4A1 (p = 0.0001, log2FC = − 1.85), were 
upregulated in AD. Table 2 lists upregulated genes, from 
the Brown-Merck database, involved in CSF production.
The Na–K-ATPase significantly impacts CSF produc-
tion [13]. Na–K-ATPase is a major pathway for  Na+ 
secretion into CSF (and  K+ uptake from CSF) [26]. 
The Na–K-ATPase transporting subunit α2, ATP1A2 
(p = 0.04, log2FC = 0.51), and the Na–K-ATPase trans-
porting subunit β1, ATP1B1 (p = 0.04, log2FC = 0.29), 
were downregulated in AD. Of all ATPase genes inves-
tigated, only ATP1A1 (p = 0.02, log2FC = − 0.45), the 
transporting subunit α1, was upregulated in AD.
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Another gene family integral to CSF production and 
homeostasis is carbonic anhydrase (CA). CA catalyzes 
production of  HCO3− and  H+ from  H2O and  CO2 [26]. 
 HCO3− is essential to CPE transport processes; thus 
proper generation of  HCO3− by CA in CPE is vital to the 
ability of the CP to secrete CSF [27]. Isoforms showed 
diverse up- and downregulation in AD. CA2 (p = 0.022, 
log2FC = 0.30), CA3 (p = 0.039, log2FC = 0.59), and CA4 
(p = 0.0001, log2FC = 0.63) were downregulated. How-
ever, CA13 (p = 0.015, log2FC = − 0.51) was upregulated. 
Other CA gene transcripts were not significantly altered.
Barrier-stabilizing genes of the claudin family, 
CLDN5 (p = 0.04, log2FC = 0.71), CLDN18 (p = 0.011, 
log2FC = 0.47) and CLDN11 (p = 0.019, log2FC = 0.65), 
were downregulated in AD. For several other claudin 
genes known or purported to be involved in epithelial 
tight junctions, a tendency towards downregulation 
was observed, although results lacked significance. 
Also downregulated was Aβ precursor protein, APP 
(p = 0.014, log2FC = 0.41). However, other CP APP 
genes (e.g., APBA3, p = 0.0015, log2FC = − 0.51) 
were upregulated. Subunits and assembly factors of 
the mitochondrial F0F1 ATP synthase, an important 
source of ATP synthesis, such as ATP5L (p = 0.0004, 
log2FC = 0.44) and ATP23 (p = 0.0008, log2FC = 0.63) 
were downregulated in AD CP. We observed no signifi-
cant changes in expression of aquaporin 4, and aqua-
porin 1 (a known passageway for passive flow of  H2O 
from CPE to ventricular lumen).
Tables  3 and 4 list genes that did not display sig-
nificant changes in expression levels between AD and 
control groups, but displayed tendencies towards 
upregulation and downregulation that may be of inter-
est for future studies.
The large number of significantly altered CP genes, 
for barrier stability, solute and  H2O transport, and pro-
duction of ATP to energize transport, makes it unlikely 
that CSF production is maintained normally in AD.
Table 1 Genes downregulated in AD CP
Positive t values for comparisons represent gene changes decreased in AD relative to control (i.e. increased in control relative to AD). The same is true for positive 
log2FC values
Gene symbol Gene name p-value t-value (control 
relative to AD)
Log2 fold change
SLC family
 SLC26A2 Solute carrier family 26 member 2; sulfate transporter 0.0000313 5.88360095 1.43830952
 SLC5A5 Solute carrier family 5 member 5; sodium/iodine cotransporter 0.0000375 5.78520397 0.75760238
 SLC4A10 Solute carrier family 4 member 10: Na-dependent Cl–HCO3 exchanger 0.0275 2.44489236 0.39339524
 SLC4A5 Solute carrier family 4 member 5: Na–HCO3 exchanger 0.00366 3.44425553 1.1215619
 SLC12A1 Solute carrier family 12 member 1: NKCC2 Na–K–Cl cotransporter 0.0353 2.31563648 1.05009524
 SLC12A2 Solute carrier family 12 member 2: NKCC1 Na–K–Cl cotransporter 0.00517 3.27527462 0.38004286
Na–K ATPase family
 ATP1A2 Na–K ATPase transporting subunit alpha 2 0.0387 2.26741686 0.50910238
 ATP1B1 Na–K ATPase transporting subunit beta 1 0.0429 2.21376353 0.29179286
Carbonic anhydrase family
 CA4 Carbonic anhydrase 4 0.000139 5.08319761 0.63055238
 CA2 Carbonic anhydrase 2 0.0222 2.55323972 0.30442619
 CA3 Carbonic anhydrase 3 0.0391 2.26309122 0.58876429
ATP synthase family
 ATP5L ATP synthase, H+ transporting, mitochondrial Fo complex subunit G 0.000419 4.51769377 0.44282857
 ATP23 ATP23 metallopeptidase and ATP synthase assembly factor homolog 0.000780 4.20573756 0.62625
 ATP5G3 ATP synthase, H+ transporting, mitochondrial Fo complex subunit C3 (subunit 9) 0.00154 3.86838238 0.65084286
 ATPAF1 ATP synthase mitochondrial F1 complex assembly factor 1 0.00269 3.59573018 0.56412619
 ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 0.0107 2.91564259 0.45252381
Tight junction claudins
 CLDN18 Claudin-18 0.0105 2.92789759 0.46640476
 CLDN11 Claudin-11 0.0190 2.63115902 0.64749762
 CLDN5 Claudin-5 0.0399 2.25235984 0.70879524
Others
 APP Amyloid beta precursor protein 0.0144 2.77007349 0.41097857
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Discussion
The basic requirements for CSF production are (i) trans-
port of ions and  H2O from CPE to the ventricular CSF 
space, (ii) production of energy to facilitate that active 
transport and (iii) an intact CP. Analysis of our Brown-
Merck GEO database revealed significantly-altered 
gene expression in AD CP that adversely impacts the 
physiology necessary for CSF secretion. Genes for ion 
Table 2 Genes upregulated in AD  CP
Negative t values are for comparisons displaying gene changes that are increased in AD relative to control (i.e. decreased in control relative to AD). The same is true for 
negative log2FC values
Gene symbol Gene name p-value t-value (control 
relative to AD)
Log2 fold change
SLC family
 SLC25A37 Solute carrier family 25 member 37: mitochondrial iron transporter 0.000128 − 5.12740967 − 0.64122381
 SLC25A28 Solute carrier family 25 member 28; mitochondrial iron transporter 0.0000927 − 5.29698098 − 0.64098333
 SLCO4A1 Solute carrier organic anion transporter family member 4A1; organic 
anion transporter
0.000103 − 5.24167279 − 1.85499048
 SLC12A7 Solute carrier family 12 member 7; KCC4 K–Cl cotransporter 0.000741 − 4.23121588 − 0.67435
 SLC12A6 Solute carrier family 12 member 6; KCC3 K–Cl cotransporter 0.0262 − 2.46864419 − 0.52261429
Interleukin-1-receptor family
 IL1R1 Interleukin-1 receptor 0.0185 − 2.64459755 − 0.62269524
 IL1RL1 Interleukin 1 receptor-like 1 0.0000113 − 6.45879688 − 3.43624762
Carbonic anhydrase family
 CA13 Carbonic anhydrase 13 0.0152 − 2.74368279 − 0.51382619
Na–K ATPase family
 ATP1A1 Na–K ATPase transporting subunit alpha 1 0.0198 − 2.61012511 − 0.45077857
Amyloid proteins
 ABPA3 Amyloid beta precursor protein (APP) binding family A member 3 0.00154 − 3.86960931 − 0.51001667
 APBB1IP APP binding family B member 1 interacting protein 0.0116 − 2.87838249 − 0.53602143
Table 3 Unchanged genes with possible tendency of downregulation in AD CP
Positive t values for comparisons represent gene changes decreased in AD relative to control (i.e. increased in control relative to AD). The same is true for positive 
log2FC values
Gene symbol Gene name p-value t-value (control 
relative to AD)
Log2 fold change
SLC family
 SLC12A4 Solute carrier family 12 member 4: KCC1 K–Cl cotransporter 0.0947 1.78492648 0.23569524
 SLC4A2 Solute carrier family 4 member 2: Cl–HCO3 exchanger 0.130 1.60190388 0.21841905
 SLC38A3 Solute carrier family 38 member 3; system N amino acid transporter 0.223 1.27232445 0.2807
Na–K ATPase family
 ATP1B2 Na–K ATPase transporting subunit beta 2 0.0533 2.09928405 0.39634524
 ATP1A4 Na–K ATPase transporting subunit alpha 4 0.684 0.41463513 0.06897143
Carbonic anhydrase family
 CA8 Carbonic anhydrase 8 0.138 1.56854024 0.50962619
 CA14 Carbonic anhydrase 14 0.172 1.4334038 0.29066667
Tight junction claudins and occludin
 CLDN1 Claudin-1 0.188 1.37904737 0.35589048
 CLDN2 Claudin-2 0.161 1.47424712 0.43342857
 CLDN3 Claudin-3 0.0942 1.78793258 0.41007381
 CLDN19 Claudin-19 0.375 0.91449198 0.32223095
 OCLN Occludin 0.799 0.25905032 0.03019762
Others
 AQP4 Aquaporin 4 0.621 0.50457389 0.18047619
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transport,  HCO3− production and barrier stability were 
downregulated in AD. Genes involved in inflammation 
and Aβ accumulation were also upregulated in AD CP. 
Altered mitochondrial enzyme and transporter expres-
sion, associated with decreased ATP production, reflects 
AD-associated metabolic- and oxidation-related defects 
at the BCSFB. All of these changes likely contribute to 
decreased CSF production in AD, though the reader must 
be aware that protein expression and mRNA expression 
are not always directly related. In addition, the reader 
should be aware that while fold changes are a good indi-
cator of the magnitude of change in gene expression, they 
do not necessarily translate to functional significance. 
Specific gene expression values for each gene in control 
and AD cases would be useful for better understand-
ing functional relevance of the gene expression changes 
detailed here; hence the provided Additional file 1 of all 
gene expression values.
Various lines of evidence suggest that Aβ accumulation 
in AD is a problem of clearance rather than overproduc-
tion [30, 31]. CSF production and turnover are part of the 
clearance mechanisms of the CNS. Communication with 
the extracellular fluid (ECF) space and the paravascular 
space [32, 33] allows the CSF pathway to function effi-
ciently as a clearance pathway.
Upregulated Aβ precursor protein binding family 
protein APBA3 in CP is consistent with plaque buildup 
[33, 34]. Aβ retention in AD CP [35] and ECF favors 
oligomerization and deposition, weakening BCSFB 
tight junctions while increasing levels of inflammatory 
cytokines and matrix metalloproteinase [21]. Aβ burden 
in the brain and its barriers may trigger microglia activa-
tion due to brain injury and promote reactive astrocytes. 
The transformation of astrocytes into neurotoxic reac-
tive cells, through increased secretion of interleukin-1α, 
tumor necrosis factor α, and complement C1q leads to 
self-perpetuating, widespread neuronal death in AD [36].
Unchecked expression of inflammatory mediators in 
response to brain tissue damage and barrier disruption 
[37] increases activation of brain microglia, and promotes 
invasion of additional immune cells through BCSFB into 
CSF and brain. CP upregulation of interleukin-1 recep-
tor (IL1R) and interleukin-1 receptor like 1 (IL1RL1) in 
AD coincides with increased IL-1 secretion by activated 
microglia. Among the cytokine families, activated IL1R 
promotes acute and chronic inflammation [38]. Antago-
nists of IL1R have potent anti-inflammatory effects [39].
Along with Aβ binding protein and IL1R upregulation, 
downregulated claudin-5, claudin-11 and claudin-18 may 
contribute to barrier degradation in AD. Claudin-5 is an 
important structural component of tight junction strands 
[40], and a gatekeeper protein regulating paracellular 
transport at BCSFB tight junctions [20]. Information 
is lacking for CP claudin-18, although high claudin-18 
expression occurs in lung alveolar epithelial tight junc-
tions [41]. Claudin-11 is an essential component of mye-
lin, and claudin-11 null mice lack myelin sheath tight 
junctions [42]. Furthermore claudin-11 downregulation 
increases BCSFB permeability to FITC-dextran [43]. 
Other claudin mRNA examined did not display signifi-
cant changes in AD CP.
Increased BCSFB transcellular and paracellular perme-
ability in AD disrupts the CP–CSF secretory, synthetic, 
and transportation functions [3]. CSF carries essential 
nutrients and ions, at homeostatic concentrations, into 
brain [44]. This enables CSF control of temperature, 
blood pressure, and pH [6].
In the context of ion transport and CSF formation, 
it is pertinent to first evaluate CP mitochondria in 
AD. AD hippocampal and CP cells are deficient in the 
Table 4 Unchanged genes with possible tendency of upregulation in AD CP
Negative t values are for comparisons displaying gene changes that are increased in AD relative to control (i.e. decreased in control relative to AD). The same is true for 
negative log2FC values
Gene symbol Gene name p-value t-value (control relative 
to AD)
Log2 fold change
SLC family
 SLC39A4 Solute carrier family 39 member 4; ZIP4 
metal ion transporter
0.806 − 0.25019879 − 0.03455714
Carbonic anhydrase family
 CA7 Carbonic anhydrase 7 0.310 − 1.05004961 − 0.16493333
 CA5B Carbonic anhydrase 5B 0.149 − 1.5231615 − 0.23130952
 CA11 Carbonic anhydrase 11 0.445 − 0.78401027 − 0.1202119
Other genes
 PSEN1 Presenilin 1 0.0687 − 1.96233878 − 0.23186667
 PSEN2 Presenilin 2 0.182 − 1.39857889, − 0.1595881
 AQP1 Aquaporin 1 0.367 − 0.93107284 − 0.11615238
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mitochondrial enzyme cytochrome c oxidase, complex 
IV of the electron transport chain [45]. Mitochondrial 
dysfunction also links to autophagy in AD. This inability 
to degrade defective macromolecules and organelles links 
with harmful neuronal lipofuscin buildup [46]. Excess 
lipofuscin in aging and in the AD CP is problematic for 
Aβ plaque formation [47, 48].
The key enzyme for ATP synthesis is mitochondrial 
ATP synthase. Choroidal ATP synthase damage indicates 
depressed ATP synthesis in AD. Even if ion transport-
ers are intact, active transporters function inefficiently 
with diminished ATP (e.g., Na–K ATPase, an important 
route for Na efflux from CPE [14], requires ATP hydroly-
sis for Na–K exchange). Thus an important consequence 
of alterations in ATP synthase subunit and assembly fac-
tor expression may be disrupted ATP-dependent active 
transport of solutes across CPE–CSF in AD, leading to 
impaired solute concentration gradients that are integral 
for CSF production. Turning to specific ion transporters, 
Na–K-ATPase is a heterodimer of an α and β subunit. 
Four α subunits and three β subunits exist in mammals 
[49]. Na–K ATPase is at the apical CPE and CSF secre-
tion is reduced by inhibiting Na–K-ATPase [26]. This 
is predictable given the Na–K-ATPase role in primary 
active  Na+ secretion into CSF (and  K+ removal from 
CSF). ATP1A1, found to be the dominant catalytic subu-
nit of the Na–K ATPase in mouse studies [50], was mildly 
upregulated in AD CP while other lesser-expressed subu-
nits ATP1A2 and ATP1B1 were downregulated. Upregu-
lation of ATP1A1 in AD CP, if it is the same in humans, 
by itself would suggest increased Na–K pumping and 
increased CSF production. However, given decreased 
CSF production in AD [1], the contribution of the Na–K 
ATPase may not be as relevant as other solute transport-
ers in CSF production disturbances in AD.
The Na–K–Cl cotransporter NKCC1, encoded by 
the SLC12A2, has an important role in solute trans-
port. NKCC1 is at the apical CPE [51]. Steffensen and 
colleagues [52] suggest that NKCC1 is responsible 
for ~ 50% of CSF production. This finding attributes a 
central role for NKCC1 in enabling  H2O to flow from 
CPE to CSF. Earlier theories proposed a simple osmotic 
model of NKCC1 coupling to an aquaporin [53, 54]. We 
observed no significant change in AQP1 and AQP4 in 
AD CP. However, CSF production declines by ~ 20% 
in AQP1 knockout (KO) mice [16], different from the 
~ 50% suggested by Steffensen et al. who theorized that 
 H2O accompanies ion flux directly through NKCC1 
[52]. Considering the likely role of NKCC1 to facili-
tate  H2O flow for CSF production, decreased NKCC1 
mRNA in AD versus control CP agrees with generally-
decreased CSF production and impaired CSF dynamics 
measured in AD [1]. We conclude that CSF dynamics 
diminution in AD is not mainly attributable to reduced 
aquaporin expression. Therefore, by deduction, altered 
 H2O movement across CPE in AD is more likely related 
to lower NKCC1 mRNA (Table 1). Still, further analy-
sis of NKCC1 transcript vs. protein expression in CP is 
needed to reconcile disparate findings [55] for AD.
Bicarbonate transport across CPE sustains CSF pro-
duction [56]. Many transporters utilize  HCO3 gradients 
to move cations and anions into and out of CPE. Aceta-
zolamide inhibition of CA distorts pH gradients among 
CPE, CSF and brain [29]. In addition, Vogh and col-
leagues established that CA inhibitors reduce CSF pro-
duction by > 50% [57]. This suggests a sizeable portion 
of CSF production depends on cell-produced  HCO3.
Na-dependent Cl–HCO3 exchange by CP SLC4A10 
gene is at the basolateral face. SLC4A10 mediates influx 
of a  Na+ and  HCO3  ion per efflux (into CP interstit-
ium) of one  Cl− ion [26]. SLC4A10 KO mice showed 
decreased ventricular volume, likely from reduced CSF 
production [58]. There was also microvilli attenuation 
and CPE cell enlargement in SLC4A10 KO mice. Given 
this study, loss of SLC4A10 in AD would be expected to 
depress CSF production. The Na–HCO3 cotransporter 
SLC4A5, downregulated in AD, is in apical CPE. There 
it mediates transport of three  HCO3 and one  Na+ from 
CPE into CSF. This stoichiometry/vector supports a 
Na–HCO3 role to counter CSF acidity while promoting 
CSF formation [59]. SLC4A5 KO mice results resem-
bled SLC4A10 KO mice in one study: decreased lateral 
ventricular volume, reduced intracranial pressure, and 
altered CPE structure [60]. However, a second SLC4A5 
study, utilizing a different KO mouse, caused arterial 
hypertension but no altered ventricular volume [61]. 
Further research needs to clarify the CSF-supporting 
role of SLC4A5, although like SLC4A10, decreased 
expression intimates reduced CSF production in AD.
Essential to  HCO3 transport is carbonic anhydrase 
activity. CA2, CA3, and CA4 were downregulated in 
AD. CA13, though, was upregulated. The CA’s generate 
 HCO3 and  H+ ions from  H2O and  CO2 [26, 29]. CA2, 
CA3 and CA13 are cytosolic while CA4 is tethered by 
a membrane anchor [62]. Of particular significance 
with respect to AD and CSF dynamics is the CA iso-
form CA2, due to its high catalytic activity and efficacy 
in proton shuttling [63]. High rates of  HCO3 produc-
tion by CA2 allow regulation of blood pH to preserve 
homeostasis. In kidneys, CA2 and CA4 associate with 
 HCO3-anion transporters and proton antiporters, 
directly coupling  HCO3-synthesis to ion exchange [62]. 
If a parallel system exists in CP, any downregulated 
CA2 and CA4 in AD CP would directly disrupt the 
action of  HCO3-anion transporters, decreasing active 
solute transport and depressing CSF formation.
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A limitation of this study is the focus on pathways we 
considered important for CSF production and the struc-
tural integrity of the CP. We therefore did not examine 
every gene in the Brown-Merck GEO database that possi-
bly impacts CSF production. Unknown genes omitted by 
us may be found by others in future CSF dynamics analy-
ses to be important. In an earlier study, Bergen et al. ana-
lyzed gene expression profiles of control and AD subjects 
based on RNA extracted from laser-dissected CPE cells 
[20]. Mining of their database may yield additional new 
insights. Comparison of their data with ours was not pos-
sible due to methodological differences. However, Stopa 
et al. analyzed common gene transcripts controlling CSF 
dynamics/homeostasis in both databases: Netherlands 
versus Brown-Merck. They reported ~ 70% agreement, 
isolated CPE versus CP tissue, with Bergen et al. [20, 24].
Conclusions
We identified multiple genes involved in CSF produc-
tion that differed in expression between AD and control 
CP. Many ion transporters that impact solute and  H2O 
transport and fluid dynamics were downregulated in 
AD. Importantly for many choroid epithelial processes, 
F0F1 ATP synthase was downregulated; this fits a dimin-
ished energy supply for choroidal transport. Genes that 
maintain CP membrane tight junctions had decreased 
expression. Upregulated CP genes in AD included those 
mediating chronic inflammation and neurodegeneration. 
Each altered gene transcript in this study is a potential 
candidate to explain the altered CSF production observed 
clinically in AD. Demonstration of causal relationships 
may lead to new therapeutic targets for AD aimed at bol-
stering CSF production and turnover.
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